BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27069173)

  • 1. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
    Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
    Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin.
    Yamamoto Y; Watanabe K; Tsukiyama I; Matsushita H; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2015 Apr; 35(4):2199-204. PubMed ID: 25862878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
    Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
    BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
    Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
    Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer.
    Yamamoto Y; Watanabe K; Matsushita H; Tsukiyama I; Matsuura K; Wakatsuki A
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1880-1886. PubMed ID: 28984058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
    Ruggiero A; Rizzo D; Trombatore G; Maurizi P; Riccardi R
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
    Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
    Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.
    Kimura T; Ozawa T; Hanai N; Hirakawa H; Suzuki H; Hosoi H; Hasegawa Y
    J Otolaryngol Head Neck Surg; 2018 Feb; 47(1):10. PubMed ID: 29394952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Magnesium premedication prevents Cisplatin-induced nephrotoxicity in patients with esophageal and hypopharyngeal cancer].
    Hirai S; Kaida S; Ito T; Hasebe S; Ueno M; Udagawa H; Hayashi M
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):743-7. PubMed ID: 23863650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
    Merouani A; Davidson SA; Schrier RW
    Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
    Morgan KP; Buie LW; Savage SW
    Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study.
    Bodnar L; Wcislo G; Gasowska-Bodnar A; Synowiec A; Szarlej-Wcisło K; Szczylik C
    Eur J Cancer; 2008 Nov; 44(17):2608-14. PubMed ID: 18796350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between magnesium pre-loading and cisplatin-induced nephrotoxicity in 5-fluorouracil/cisplatin combination therapy for esophageal cancer.
    Sugisaki T; Aoyama T; Kawakami K; Yokokawa T; Kobayashi K; Suzuki W; Ogura M; Ichimura T; Chin K; Yamaguchi K; Hanaoka S; Hayashi H; Yamaguchi M
    Pharmazie; 2022 Feb; 77(2):85-88. PubMed ID: 35209969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
    Crona DJ; Faso A; Nishijima TF; McGraw KA; Galsky MD; Milowsky MI
    Oncologist; 2017 May; 22(5):609-619. PubMed ID: 28438887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
    Ohhara Y; Isobe H; Ito K; Fuke S; Kojima T; Saito H; Nishiura Y
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):57-61. PubMed ID: 25596680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis.
    Yamaguchi T; Uozu S; Isogai S; Hayashi M; Goto Y; Nakanishi T; Imaizumi K
    Support Care Cancer; 2017 Apr; 25(4):1215-1220. PubMed ID: 27966021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
    Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
    Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.